In addition to first-line therapy for metastatic colon cancer, the ML18147 study demonstrated clinical benefit in patients with metastatic colorectal cancer by maintaining a vascular endothelial growth factor inhibitor (bevacizumab) with standard second-line chemotherapy after disease progression (Bennouna et al., 2013). The gene discussed is VEGFA; the disease is metastatic colorectal cancer.